IMNM vs IMVT: fair value comparison
Immunome, Inc. and Immunovant, Inc. · Updated 2026-10-19
IMNM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. IMVT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IMNM currently ranks higher by quality score.
| IMNM | IMVT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $16.47 | $26.73 |
| 12-month range | $15.24–$29.82 | $18.74–$44.96 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #242 of 301 Healthcare | #243 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | — |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: IMNM fair value analysis · IMVT fair value analysis